Petlife Pharmaceuticals Inc (PTLF) 0.1950 $PTLF
PetLife Pharmaceuticals Adds Seasoned Medical Professionals to the Management Team
GlobeNewswire - Mon Jul 25, 7:01AM CDT
PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"
, a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the additions of Dr. Joel Beth Mitchel-Navratik, Vice President of Veterinary Affairs, and Dr. Vivek Ramana, Chief Medical Officer, to the management team.
PetLife Pharmaceuticals Provides Positive Update to Shareholders
GlobeNewswire - Mon Oct 05, 8:06AM CDT
Highlights:
PetLife Pharmaceuticals Provides Shareholder Update
Marketwired - Thu Mar 26, 7:30AM CDT
PetLife Pharmaceuticals, Inc. (OTC PINK: PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today issued the following Special Letter to Shareholders:
Petlife Pharmaceuticals Announces That Escozine for Human Cancer Treatment Gains Acceptance from Insurance Company in Vietnam
ACCESSWIRE - Thu Dec 18, 7:30AM CST
BEVERLY HILLS, CA / ACCESSWIRE / December 18, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of new generation high potency veterinary cancer medications and nutraceuticals for pets, today announced that its affiliate company, Medolife Corp., has negotiated an agreement with a new distributor in Vietnam that has an agreement with a health insurance company to cover the cost of patients using the company's Escozine cancer treatment product as part of their cancer therapy.
PetLife Announces Positive Developments in Special Letter to Shareholders
ACCESSWIRE - Thu Dec 11, 7:31AM CST
Beverly Hills, CA / ACCESSWIRE / December 11, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today issued the following Special Letter to Shareholders:
Miami Vets Lead Alternative Pet Cancer Treatment with Escozine for Pets(TM)
ACCESSWIRE - Mon Nov 10, 8:29AM CST
Beverly Hills, CA / ACCESSWIRE / November 10, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today reported it is seeing Miami-area veterinarians leading the growing trend toward studying and using more cutting-edge treatment of pets to include increasing use of the Company's Escozine for Pets nutraceutical product to treat pets with cancer.
PetLife Reports Positive Veterinary Clinical Pet Data on Escozine for Pets; Cancer-Diagnosed Pets' Quality, and Longevity, of Life Improved and Extended
ACCESSWIRE - Mon Nov 03, 7:32AM CST
Beverly Hills, CA / ACCESSWIRE / November 3, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has received positive, preliminary clinical research data from an ongoing study of ten dogs or cats -- diagnosed with cancer - that are being treated with Escozine for Pets(TM). The Study is conducted by Raul Jimenez, DVM, of the prestigious Biscayne Veterinary Center in Miami.
PetLife Pharmaceuticals Adds Seasoned Medical Professionals to the Management Team
GlobeNewswire - Mon Jul 25, 7:01AM CDT
PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"
, a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the additions of Dr. Joel Beth Mitchel-Navratik, Vice President of Veterinary Affairs, and Dr. Vivek Ramana, Chief Medical Officer, to the management team. PetLife Pharmaceuticals Provides Positive Update to Shareholders
GlobeNewswire - Mon Oct 05, 8:06AM CDT
Highlights:
PetLife Pharmaceuticals Provides Shareholder Update
Marketwired - Thu Mar 26, 7:30AM CDT
PetLife Pharmaceuticals, Inc. (OTC PINK: PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today issued the following Special Letter to Shareholders:
Petlife Pharmaceuticals Announces That Escozine for Human Cancer Treatment Gains Acceptance from Insurance Company in Vietnam
ACCESSWIRE - Thu Dec 18, 7:30AM CST
BEVERLY HILLS, CA / ACCESSWIRE / December 18, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of new generation high potency veterinary cancer medications and nutraceuticals for pets, today announced that its affiliate company, Medolife Corp., has negotiated an agreement with a new distributor in Vietnam that has an agreement with a health insurance company to cover the cost of patients using the company's Escozine cancer treatment product as part of their cancer therapy.
PetLife Announces Positive Developments in Special Letter to Shareholders
ACCESSWIRE - Thu Dec 11, 7:31AM CST
Beverly Hills, CA / ACCESSWIRE / December 11, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF), a developer of new generation of high potency veterinary cancer medications and nutraceuticals for pets, today issued the following Special Letter to Shareholders:
Miami Vets Lead Alternative Pet Cancer Treatment with Escozine for Pets(TM)
ACCESSWIRE - Mon Nov 10, 8:29AM CST
Beverly Hills, CA / ACCESSWIRE / November 10, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today reported it is seeing Miami-area veterinarians leading the growing trend toward studying and using more cutting-edge treatment of pets to include increasing use of the Company's Escozine for Pets nutraceutical product to treat pets with cancer.
PetLife Reports Positive Veterinary Clinical Pet Data on Escozine for Pets; Cancer-Diagnosed Pets' Quality, and Longevity, of Life Improved and Extended
ACCESSWIRE - Mon Nov 03, 7:32AM CST
Beverly Hills, CA / ACCESSWIRE / November 3, 2014 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) today announced it has received positive, preliminary clinical research data from an ongoing study of ten dogs or cats -- diagnosed with cancer - that are being treated with Escozine for Pets(TM). The Study is conducted by Raul Jimenez, DVM, of the prestigious Biscayne Veterinary Center in Miami.
